Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01468350 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy
A Phase 1 study, sponsored by Acorda Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT01468350 is a Phase 1 study that has completed, run by Acorda Therapeutics. The registered enrollment target is 35 participants.
The verdict
NCT01468350, a Phase 1 study, has completed, sponsored by Acorda Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
A double-blind, placebo-controlled, crossover study in subjects with cerebral palsy (CP) to evaluate the safety and tolerability and the effect of dalfampridine extended release (ER) tablets on sensorimotor function
Interventions
- OTHER Placebo
- DRUG dalfampridine-ER 10mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2011-12 |
| Est. Completion | 2013-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01468350
The ClinicalTrials.gov registry entry for NCT01468350 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Acorda Therapeutics, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01468350 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01468350 about?
NCT01468350 is a clinical study titled "Safety and Tolerability of Dalfampridine in Subjects With Cerebral Palsy". A double-blind, placebo-controlled, crossover study in subjects with cerebral palsy (CP) to evaluate the safety and tolerability and the effect of dalfampridine extended release (ER) tablets on sensorimotor function
What is the current status of trial NCT01468350?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2011-12. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01468350?
The interventions under investigation include: Placebo (OTHER), dalfampridine-ER 10mg (DRUG).
Who is sponsoring clinical trial NCT01468350?
This trial is sponsored by Acorda Therapeutics, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.